Moderate to severe psoriasis
Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
... of psoriasis can be profound. The extent to which psoriasis affects a person’s health-related quality of life (HRQoL) is similar to that of other chronic diseases, such as arth- ritis, chronic lung disease, ...
9
Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
... with moderate-to-severe psoriasis were ran- domized to receive a single subcutaneous (SC) dose of brodalumab 140 mg (n = 4), a single SC dose of 350 mg (n = 8), a single intravenous (IV) dose of 700 ...
9
Infliximab Therapy in Iraqi Patients with Moderate to Severe Psoriasis
... with moderate-to-severe ...with moderate-to-severe psoriasis resistant to conventional treatments were enrolled to receive infusions of infliximab 5 mg/kg at weeks 0, 2, and 6, then ...
8
<p>Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review</p>
... The clinical ef fi cacy and safety of brodalumab have been demonstrated in the AMAGINE controlled clinical trials. 15,16 AMAGINE-2 and − 3 were replicate phase 3, international, multicenter, randomized, double-blind, ...
9
Therapy of moderate and severe psoriasis Therapie der mittelschweren und der schweren Psoriasis
... A numerically meaningful scientific discussion about economic questions in therapy of moderate and severe psoriasis in terms of publications started at end of the 90ies. Beside economic analysis also ...
10
A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
... of moderate-to-severe plaque-type psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic ...less severe severity classes compared ...
7
Association between moderate to severe psoriasis and periodontitis in a Scandinavian population
... Periodontitis is a cumulative condition and therefore radiographic bone loss, capturing past history of disease, was used in addition to the clinical registration of peri- odontal status. Clinical examiners were not ...
9
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
... with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 ...
9
Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
... for moderate to severe psoriasis when compared to other biologi- cals indicated for the same type of psoriasis, as it does not inhibit or directly deplete ...
8
<p>Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date</p>
... Scalp psoriasis has a large negative impact on psychosocial aspects and overall quality of life of patients with moderate-to- severe ...the psoriasis patients 3 and is considered among the dif ...
5
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study
... of moderate to severe psoriasis patients often include both physician-assessed clinical endpoints and dermatology-specific patient-reported outcomes (PROs) to obtain a holistic view of the disease ...
12
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
... Based on clinical trial data, secukinumab is currently the most efficacious biologic available for the treatment of moderate-to-severe psoriasis with a comparable safety profile to existing ...
9
Epidemiology and treatment of psoriasis: a Brazilian perspective
... of moderate-to-severe ...for moderate-to-severe psoriasis is not mandatory for private health insurers in Brazil; only combination of psoralen (P) and long-wave ultraviolet radiation ...
10
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
... larger psoriasis population; however, this study includes the largest population of patients with moderate-to-severe psoriasis with characterization of skin gene expression with simultaneous ...
8
<p>Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</p>
... safer psoriasis therapies has resulted in a treatment shift from oral immunosuppressants to more targeted biologic and small molecule medications for patients inadequately con- trolled on a topical regimen or ...
8
<p>Therapeutic drug monitoring of biologics in psoriasis</p>
... Guselkumab and tildrakizumab are novel monoclonal anti- bodies targeting interleukin-23, a key regulator in the patho- physiology of psoriasis. It bridges the innate and adaptive immune responses and plays a key ...
6
Etanercept in psoriasis: the evidence of its therapeutic impact
... for psoriasis treatments affect patients’ expenses (Simpson et ...with moderate to severe psoriasis who have failed methotrexate therapy are likely to benefit from etanercept treatment in a ...
12
Targeting IL-23 in psoriasis: current perspectives
... 30. Blauvelt A, Papp KK, Griffiths CE, et al. Efficacy and safety of gusel- kumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for continuous treatment of patients with moderate-to- ...
5
Vol 32, No 3 (2019)
... Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively ...
5
A REVIEW ON TOPICAL THERAPEUTICS IN PSORIASIS
... the psoriasis is topical application of various ...to moderate psoriasis and are well tolerated on the face and intertriginous areas without the use of ...For moderate to severe ...
13